Coexisting Pulmonary Tuberculosis and Mucormycosis in a Patient with Aplastic Anemia Post Allogenic Stem Cell Transplantation by Sharma, Sanjeev Kumar et al.
Mediterr J Hematol Infect Dis 2011; 3; Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Case Reports  
Coexisting Pulmonary Tuberculosis and 
Anemia Post Allogenic Stem Cell Transplan
Sanjeev Kumar Sharma
1, Narendra Agarwal
Manoranjan Mahapatra
1 and Sanjay Sharma
Department of 
1Hematology, 
2Microbiology and 
Delhi, India
Correspondence to: Sanjay Sharma, MD
New Delhi-110029, IndiaPhone: 91-9868398804 
Competing interests: The authors have declared th
Published: September 8, 2011
Received: June 30, 2011
Accepted: July 22, 2011
Mediterr J Hematol  Infect Dis 2011, 3: e201
This article is available from: http://www.mjhid.org/article/view/8772
This  is  an  Open  Access  article  distributed  under  the
(http://creativecommons.org/licenses/by/2.0
provided the original work is properly cited
   
Infections are the most common cause of morbidity and mortality in allogenic stem cell transplant 
recipients. Survival of the patient depends on the accurate diagnosis of the infectious agents and 
prompt  and  effective  managemen
immunosuppression  post  transplantation.  We  here  reported  a  case  of  aplastic  anemia  who 
developed left upper lobe consolidation post allogenic stem cell transplantation and was found to 
have combined infection with tuberculosis and mucormycosis. This is the first case of combined 
infection with tuberculosis and mucormycosis reported in such a host, with a favourable outcome
Mucormycosis  is  a  dreaded  complication  in 
immunocompromised  patients  particularly  following 
chemotherapy or stem cell transplantation, and can be 
highly  fatal  if  not  treated  urgently.
1
which is particularly common in developing countries
is  now  being  increasingly  recognised  in  transplant 
recipients,  can  pose  both  diagnostic  and  therapeutic 
challenges  in  such  patients.
2 We  report  a  case  of 
aplastic  anemia  who  developed  left  upper  lobe 
consolidation post  allogenic  stem cell  transplantation
and  was  found  to  have  combined  infection  with 
tuberculosis  and  mucormycosis.  Although  isolated 
infections  by  tuberculosis  and  mucormycosis  have 
been  reported  in  transplant  recipients,  combined 
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Infections are the most common cause of morbidity and mortality in allogenic stem cell transplant 
recipients. Survival of the patient depends on the accurate diagnosis of the infectious agents and 
prompt  and  effective  management  of  the  infection  alongwith  maintenance  of  adequate 
immunosuppression  post  transplantation.  We  here  reported  a  case  of  aplastic  anemia  who 
developed left upper lobe consolidation post allogenic stem cell transplantation and was found to 
ction with tuberculosis and mucormycosis. This is the first case of combined 
infection with tuberculosis and mucormycosis reported in such a host, with a favourable outcome
Mucormycosis  is  a  dreaded  complication  in 
immunocompromised  patients  particularly  following 
chemotherapy or stem cell transplantation, and can be 
1    Tuberculosis, 
which is particularly common in developing countries, 
is  now  being  increasingly  recognised  in  transplant 
recipients,  can  pose  both  diagnostic  and  therapeutic 
We  report  a  case  of 
aplastic  anemia  who  developed  left  upper  lobe 
consolidation post  allogenic  stem cell  transplantation
and  was  found  to  have  combined  infection  with 
tuberculosis  and  mucormycosis.  Although  isolated 
infections  by  tuberculosis  and  mucormycosis  have 
been  reported  in  transplant  recipients,  combined 
infection  with  both  simultaneously  in  transplant 
recipients has not yet been reported.
A  26-years  old  lady  presented  with  progressive 
weakness and fever for 3 months, and was found to 
have  pancytopenia  (hemoglobin  6.5g/dl,  total 
leukocyte  count  2.8x10
9/l,  neutrophils  12%  and 
lymphocytes 88% and platelet counts 13x10
marrow  biopsy  revealed  cellularity  of  5%.  She  was 
diagnosed  severe  aplastic  anemia  and  had  HLA 
matched  sibling.  She  underwent  allogenic  peripheral 
blood  stem  cell  transplantation  (PBSCT)  from  the 
matched sibling donor,   with 
including fludarabine 30mg/m
10  to  day  -5)  and  cyclophosphamide  60mg/m
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ction with tuberculosis and mucormycosis. This is the first case of combined 
infection with tuberculosis and mucormycosis reported in such a host, with a favourable outcome
infection  with  both  simultaneously  in  transplant 
s not yet been reported.
years  old  lady  presented  with  progressive 
weakness and fever for 3 months, and was found to 
have  pancytopenia  (hemoglobin  6.5g/dl,  total 
/l,  neutrophils  12%  and 
lymphocytes 88% and platelet counts 13x10
9/l). Bone 
marrow  biopsy  revealed  cellularity  of  5%.  She  was 
diagnosed  severe  aplastic  anemia  and  had  HLA 
matched  sibling.  She  underwent  allogenic  peripheral 
blood  stem  cell  transplantation  (PBSCT)  from  the 
with   conditioning    regimen
including fludarabine 30mg/m
2 for 6 days (from day -
5)  and  cyclophosphamide  60mg/m
2  for  2 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
days (day -6 and day -5). The CD34+ cell dose given 
was  4.8x10
6/kg.    Graft  versus  host  disease  (GVHD) 
prophylaxis  included  horse  anti-thymocyte  globulin 
(ATGAM
® Pfizer) 30mg/kg/day for 4 days (day -4 to 
day -1), methotrexate (10mg/m
2) on day+1, +3 and +6, 
and  cyclosporine  100mg  twice  daily  intravenously 
from day -1 with  dose adjusted according to plasma 
cyclosporine levels (between 150-300ng/ml). She was 
given  oral  levofloxacin  500mg  daily,  fluconazole 
400mg  daily,  aciclovir  400mg  twice  daily  and 
trimethoprim-sulfamethoxazole 480 mg q12 hours on 
alternate days as prophylaxis. She developed fever on 
day  +4  of  transplant  and  was  started  on  piperacillin 
plus  tazobactum  (4.5g  i.v.  q  6  hours)  and  amikacin 
(750mg i.v. q 24 hours). Chest radiograph was normal,
and blood and urine cultures were sterile. She became 
afebrile on day +7. She engrafted on day +10 (absolute 
neutrophil  count  >0.5x10
9/l  and  unsupported  platelet 
count > 20x10
9/l). On day + 17 she developed fever 
with dry cough and left sided chest pain. Computerized 
tomography (CT) scan of the chest showed left upper 
lobe  consolidation  with  surrounding  ground  glass 
opacity. (Figure 1)
Figure 1: Axial  CT chest showing  left upper  lobe consolidation 
with surrounding ground glass opacity (shown by arrow).
Oral voriconazole (400mg twice daily on the first 
day followed by 200mg twice daily) was emperically 
started and fluconazole was stopped. Bronchoalveolar 
lavage  showed the presence  of  acid  fast  bacilli 
suggestive  of  mycobacterium  tubercular  infection 
(Figure  2). On  day  +19  she  was  started  on  anti-
tubercular therapy (ATT) (isoniazid 300mg, rifampicin 
450mg, ethambutol 1000mg and pyrizinamide 1500mg 
daily). 
Considering  high  risk  of  fungal  infection  and
Figure 2: Acid Fast Bacilli in smear stained by ZN stain (shown by 
arrow) prepared from BAL sample of the patient after concentration 
and decontamination (X1000 under oil immersion).
interactions of voriconazole with anti-tubercular drugs, 
lung  biopsy  was  performed  3  days  later,  which
revealed  broad  aseptate  hyphae  branching  at a right 
angle suggestive of mucormycosis (Figure 3). She was 
started on liposomal amphotericin B (3mg/kg/day) and 
voriconazole  was  stopped.  With  continued liposomal 
amphotericin  B  along with  anti-tubercular  drugs, the 
lesion started decreasing in size, and surgical resection 
was  deferred.  Patient  became  afebrile  2  weeks latter 
and  follow-up  CT  scan  and  sequential  chest 
radiographs showed a significant reduction in the size 
of  the lesion. 
On day +28 of transplant, patient developed renal 
dysfunction (serum creatinine 1.8mg/dl) and peripheral 
smear showed schistocytes. Cyclosporine was stopped 
in  view  of  drug  induced  microangiopathy  and 
mycophenolate mofetil 1000mg twice daily was started
which she tolerated well.   
Figure  3:  Aseptate,  irregular,  ribbon-like,  broad,  wide-angled 
branching  hyphae  suggestive  of  mucormycosis  in  lung  tissue 
(shown by arrow) (H & E X200).  Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
She was continued on liposomal amphotericin B for 
8  weeks and had nearly complete  resolution of lung 
lesion.  ATT  was  stopped  6  months  later. 
Mycophenolate  mofetil  was  stopped  18  months  post 
transplant. She did not develop acute GVHD but had 
onset  of  limited  chronic  skin  GVHD  in  7
th month 
which  was  controlled  with  steroids  (prednisolone 
1mg/kg/day for 4 weeks and then in tapering doses for 
next 2 months), without reactivation of tuberculosis or 
mucormycosis. Patient is now 2 years post stem cell 
transplant  with  hemoglobin  12.5g/dl,  total  leukocyte
count 8.6x10
9/l and platelet counts 192x10
9/l, with no 
sequele related to chest infection or GVHD.
Mucormycosis  is  rare  in  allogenic transplant 
recipients  with  an incidence  of  1.9%  reported  in  a 
series of 263 patients.
1 The incidence of mycobacterial 
infection  among  stem  cell  transplant  recipients  has 
been estimated to be 0.6%-9.7% in United States
2 but 
the  incidence  in  developing  countries  may  be  even 
higher where tuberculosis is endemic.
3 
Our case highlights certain important facts. First, a 
high index of suspicion of tuberculosis should be kept 
in  patients  with  upper  lobe  consolidations.  Second, 
invasive  fungal  infections,  particularly  aspergillosis 
and rarely mucormycosis may occur in post transplant 
immunocompromised state and distinction between the 
two  is  very  important  as  treatment  differs. 
Voriconazole is the treatment of choice for aspergillus 
but  is  ineffective  against  mucormycosis  which 
responds  to  amphotericin  and  may  even  require 
surgical  debridement.    Posaconazole  has  also  been 
shown to be effective against mucormycosis. Thirdly, 
drug-to-drug  interactions  are  very  common  when 
antitubercular  drugs  (e.g.  rifampicin)  are  being  used 
with antifungal (voriconazole) and immunosuppressive 
drugs  (cyclosporine).  Infection  has  to  be  treated 
adequately and simultaneously immunosuppression has 
to  be  maintained  to  prevent  graft  rejection. 
Bronchoalveolar lavage and lung biopsy both helped in 
detecting the causative organisms in our case leading to 
appropriate  treatment.  Both  tuberculosis
4 and 
mucormycosis
5 have  been  reported  as  late 
complications following transplantation but our patient 
developed these infections early after transplantation. 
Rifampicin increases the  metabolism  of  cyclosporine 
and so dose of latter has to be modified according to 
plasma levels. Toxicity of multiple drugs, particularly 
affecting  renal  and  hepatic  functions,  can  occur  and 
requires  careful  monitoring  of  these  organs.  With 
increasing  number  of  patients  undergoing 
transplantations in developing countries, the endemic 
diseases also need to be considered while looking for 
the  usual  infections  in  immunocompromised  post 
transplant  recipients  and  mixed  infections  are  a 
possibility.  Diagnosis  of  mixed  infections  is 
challenging and requires a high index of suspicion and 
adequate management for better outcome, particularly 
when there is an emerging trend of fungal infections in 
patients with pulmonary tuberculosis.
6
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